StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera BGI Genomics Remaining Performance Obligations by Year

BGI Genomics Remaining Performance Obligations — RPO ($M) [legacy through Q1 2025] ($M)

Natera BGI Genomics Remaining Performance Obligations: $20M in FY2024, up 233.3% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2024
20
Period ended Dec 31, 2024
Change on a year earlier
+233.3%
6 in FY2023
History
2 years
Since FY2023
Sources
2
Documents cited below

Where the FY2024 figure comes from

Source: Form 10-Q (2026-08-07) ↗

Reported in Form 10-K/10-Q Note — Remaining Performance Obligations (2023–2025Q1).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBGI Genomics Remaining Performance Obligations — RPO ($M) [legacy through Q1 2025] ($M)Year on yearSource
FY2024Dec 31, 202420+233.3%Form 10-Q (2026-08-07) ↗
FY2023Dec 31, 20236–Form 10-K (2024-02-29) ↗

Cite this data

StockData. (2026). Natera BGI Genomics Remaining Performance Obligations ($M), annual FY2023–FY2024 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rpo-bgi-total

See every metric in the Natera KPI table. Data updated Nov 2, 2026.